Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 2/20 | 0.68 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | POLB | P06746 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | RAD52 | P43351 | 1/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.67 |
| ▸ | CA12 | O43570 | 3/20 | 0.61 |
| ▸ | CA1 | P00915 | 3/20 | 0.61 |
| ▸ | CA2 | P00918 | 3/20 | 0.61 |
| ▸ | CA9 | Q16790 | 3/20 | 0.61 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.58 |
| ▸ | NGFR | P08138 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3853314 | 0.93 | MEN1 (0.69) | FTOPABPC1MEN1KMT2APOLB | |
| SCHEMBL5107206 | 0.92 | FTO (0.64) | FTOPABPC1MEN1KMT2APOLB | |
| SCHEMBL2023426 | 0.91 | FTO (0.63) | FTOPABPC1MEN1KMT2APOLB | |
| SCHEMBL3852391 | 0.90 | FTO (0.53) | FTOPABPC1MEN1KMT2APOLB | |
| SCHEMBL5116172 | 0.88 | MEN1 (0.66) | FTOPABPC1MEN1KMT2APOLB | |
| SCHEMBL1901643 | 0.86 | FTO (0.72) | FTOPABPC1MEN1KMT2APOLB | |
| SCHEMBL3850831 | 0.85 | FTO (0.64) | FTOPABPC1MEN1KMT2APOLB | |
| SCHEMBL3861437 | 0.84 | FTO (0.69) | FTOPABPC1MEN1KMT2APOLB | |
| SCHEMBL2285573 | 0.84 | FTO (0.72) | FTOPABPC1MEN1KMT2APOLB | |
| SCHEMBL1893251 | 0.84 | FTO (0.72) | FTOPABPC1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221147-A1 | Method of inhibiting neurotrophin-receptor binding | ROSS GREGORY M | 2008-09-11 | — | — | US | disclosed |
| EP-1743886-A1 | Method of inhibiting neurotrophin-receptor binding | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2007-01-17 | — | — | EP | disclosed |
| US-20060063793-A1 | Method of inhibiting neurotrophin-receptor binding | ROSS GREGORY M | 2006-03-23 | — | — | US | disclosed |
| CN-1246323-C | Nitrogen-based camptothecin derivatives | CALIFORNIA PACIFIC MED CENTER (US) | 2006-03-22 | — | — | CN | disclosed |
| CN-1511159-A | Nitrogen-based camptothecin derivatives | ����������̫ƽ��ҽѧ���� | 2004-07-07 | — | — | CN | disclosed |
| US-20030203923-A1 | Method of inhibiting neurotrophin-receptor binding | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2003-10-30 | — | — | US | disclosed |
| US-6492380-B1 | Method of inhibiting neurotrophin-receptor binding | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-12-10 | — | — | US | disclosed |
| US-6462023-B1 | SUCH AS 2-HYDROXY-HYDROXYCARBAMOYL-METHYL)-4-METHYL-PENTANOYLAMINE)-2-PHENYL -ETHANOIC ACID CYCLOPENTYL ESTER; INHIBITING HYPERPROLIFERATIVE TUMOURGENIC CELLS SUCH AS MELANOMA AND/OR LYMPHOMA CELLS | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2002-10-08 | — | — | US | disclosed |
| EP-1185515-A1 | METHOD OF INHIBITING NEUROTROPHIN-RECEPTOR BINDING | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000069828-A1 | METHOD OF INHIBITING NEUROTROPHIN-RECEPTOR BINDING | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063793-A1 | Method of inhibiting neurotrophin-receptor binding | NGF, NTRK2, BDNF | FTO 2107/4885PABPC1 4029/4885MEN1 3489/4885 |
| US-20030203923-A1 | Method of inhibiting neurotrophin-receptor binding | NGF, NTRK2, BDNF | FTO 2078/4885PABPC1 3895/4885MEN1 3799/4885 |
| US-20080221147-A1 | Method of inhibiting neurotrophin-receptor binding | NGF, NTRK2, BDNF | FTO 2107/4885PABPC1 4029/4885MEN1 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.